Luminex ’s Post

🔬 GenomeWeb Interviews Novelna CEO on our MCED Test for Cancer Screening ✨ Featured on GenomeWeb, January 12, 2024 ✨ In a recent interview with GenomeWeb, our CEO, Ashkan Afshin, MD ScD, spoke about Novelna's innovative approach to cancer diagnostics. He highlighted our team's vision for developing a more affordable and sensitive multi-cancer early detection (MCED) test. Departing from DNA-based or multiomics methods, Novelna's approach focuses on using low-abundance proteins. This strategy is designed to enhance the accuracy of cancer screening while reducing costs, thereby making it more accessible, especially for asymptomatic individuals. Our initial proof of concept study, led by Bogdan Budnik from Harvard's Wyss Institute, has been published in BMJ Oncology. This research introduces two sex-specific panels for cancer detection, demonstrating promising results in the early detection of cancer. In his interview, Afshin elaborated on the challenges and immense potential of proteomics in cancer screening. This development is an important step toward enhancing technology and improving the accessibility of advanced healthcare. 🔗 Read the full article on GenomeWeb here: https://lnkd.in/gBxvmfeX #Novelna #DemocratizingDiagnostics #Proteomics #Diagnostics #CancerScreening #LiquidBiopsy #EarlyDetection #BMJOncology

EG BioMed R&D Team Discovers the Key to Revolutionizing Breast Cancer Monitoring Discovering the perfect biomarker for cancer progression is like finding a needle in a haystack. But with cutting-edge genomic technologies and a global perspective, we’ve found that needle. Through the use of Illumina methylation arrays, researchers analyzed breast tumor samples from Taiwanese patients and cross-referenced them with data from The Cancer Genome Atlas (TCGA) in Western countries. The EG BioMed R&D team, using this comprehensive analysis, unveiled TMEM240 as a standout candidate. Clinical validation has shown that elevated levels of circulating methylated TMEM240 are directly linked to the presence of cancer cells, making it a powerful, non-invasive tool for tracking cancer progression. This discovery not only enhances our understanding of cancer biology but also paves the way for more personalized and effective treatment strategies. Published in Molecular Medicine 28: 67 (2022).

On #NationalCancerAwarenessDay, explore our eBook to learn about some of the latest work utilizing proteomics to advance cancer research, and how proteomics could drive the creation of much-needed diagnostics and treatments for a variety of cancers, including:    ◾ Lung Cancer  ◾ Breast Cancer  ◾ Prostate Cancer  ◾ Pancreatic Cancer  ◾ Epithelial Cancer  ◾ Colon Cancer     Read and download now 📘 https://lnkd.in/d5s4kT4z     #UnleashTheProteome #Proteomics #CancerResearch #PrecisionMedicine 

In a 2020 study of lung adenocarcinoma, Broad Institute of MIT and Harvard’s Michael Gillette, Shankha S., Steven Carr and colleagues used a multiomics approach to identify potentially druggable pathways, determinants of immune cell invasion, and connections between omics levels in non-small cell lung cancer.    Learn more about the applications of their extensive data set on our blog, including how that data can be leveraged for studies of lung cancer biology, biomarkers, and treatments: https://lnkd.in/ghZ88bWz     #UnleashTheProteome #ProteomicsRevolution #Proteomics #Multiomics #LungCancer #CancerResearch 

The future of cancer research is being revolutionized by precision medicine, targeted therapies, and an increased focus on pediatric and aggressive cancers. Technological advancements such as nanotechnology and gene-editing are redefining cancer treatments, with organizations like the AACR driving continuous innovation. Further research into the complex genetics of cancer is enabling personalized therapies and early detection strategies, bringing us closer to a future where cancer could become a manageable disease.

🌟 Exciting Review on Cancer Biomarkers Published in Cell A groundbreaking review marking the 50th anniversary of Cell magazine has been shared, & it's a must-read for anyone interested in the evolving landscape of oncology biomarkers. "Cancer biomarkers: Emerging trends and clinical implications for personalized treatment" meticulously synthesizes main research & collaborative expertise of leaders in the field. 🎯 Highlights: 🧬Integration of Biomarkers: how cancer biomarkers are crucial for the shift towards personalized treatment in oncology. 💊Tailored Therapies: It stresses the empowerment of oncologists to customize treatments based on the molecular makeup of tumors, heralding a new era in precision oncology. 🔭Future Horizons: The authors discuss the future of managing solid tumors, driven by innovations in profiling circulating tumor fractions & understanding the immune microenvironment. 🔗 Full article free here 👇👇👇: https://lnkd.in/eqgSnN_8 ⚕️A tip of the hat to the authors for this enlightening synthesis Antonio Passaro fabrice andre Peters Solange et al. #ESMO #PrecisionOncology #CancerResearch #Cell #biomarkers #genomics #WGS #ctDNA #liquidbiopsy

Excited to share our latest research breakthrough! In our newly published article in the esteemed journal "Cancer Reports," titled "UBE2C: A pan-cancer diagnostic and prognostic biomarker revealed through bioinformatics analysis," we delve into the discovery of a promising biomarker with profound implications for cancer diagnosis and prognosis. Our study identified UBE2C as the sole gene exhibiting significant differential expression across various cancer types analyzed from TCGA datasets. This finding underscores the potential of UBE2C as a universal diagnostic and prognostic marker for diverse cancers. Through rigorous bioinformatics analyses, we unveil the intricate role of UBE2C, shedding light on its utility as a reliable indicator for detection and prognosis assessment in cancer patients. The implications of this discovery are far-reaching, offering new avenues for personalized treatment strategies and improved patient outcomes. Join us in advancing cancer research and precision medicine by exploring the transformative potential of UBE2C as a pan-cancer biomarker. Read the full article to dive deeper into the implications of our findings and their implications for the future of oncology. #CancerResearch #PrecisionMedicine #Bioinformatics #UBE2C

🌟 Exciting Review on Cancer Biomarkers Published in Cell A groundbreaking review marking the 50th anniversary of Cell magazine has been shared, & it's a must-read for anyone interested in the evolving landscape of oncology biomarkers. "Cancer biomarkers: Emerging trends and clinical implications for personalized treatment" meticulously synthesizes main research & collaborative expertise of leaders in the field. 🎯 Highlights: 🧬Integration of Biomarkers: how cancer biomarkers are crucial for the shift towards personalized treatment in oncology. 💊Tailored Therapies: It stresses the empowerment of oncologists to customize treatments based on the molecular makeup of tumors, heralding a new era in precision oncology. 🔭Future Horizons: The authors discuss the future of managing solid tumors, driven by innovations in profiling circulating tumor fractions & understanding the immune microenvironment. 🔗 Full article free here 👇👇👇: https://lnkd.in/dCAx4Rkp ⚕️A tip of the hat to the authors for this enlightening synthesis Antonio Passaro fabrice andre Peters Solange et al. #ESMO #PrecisionOncology #CancerResearch #Cell #biomarkers #genomics #WGS #ctDNA #liquidbiopsy

🌟 Exciting Review on Cancer Biomarkers Published in Cell A groundbreaking review marking the 50th anniversary of Cell magazine has been shared, & it's a must-read for anyone interested in the evolving landscape of oncology biomarkers. "Cancer biomarkers: Emerging trends and clinical implications for personalized treatment" meticulously synthesizes main research & collaborative expertise of leaders in the field. 🎯 Highlights: 🧬Integration of Biomarkers: how cancer biomarkers are crucial for the shift towards personalized treatment in oncology. 💊Tailored Therapies: It stresses the empowerment of oncologists to customize treatments based on the molecular makeup of tumors, heralding a new era in precision oncology. 🔭Future Horizons: The authors discuss the future of managing solid tumors, driven by innovations in profiling circulating tumor fractions & understanding the immune microenvironment. 🔗 Full article free here 👇👇👇: https://lnkd.in/dp-9sf_v ⚕️A tip of the hat to the authors for this enlightening synthesis Antonio Passaro fabrice andre Peters Solange et al. #ESMO #PrecisionOncology #CancerResearch #Cell #biomarkers #genomics #WGS #ctDNA #liquidbiopsy

The future of cancer research is being revolutionized by precision medicine, targeted therapies, and an increased focus on pediatric and aggressive cancers. Technological advancements such as nanotechnology and gene-editing are redefining cancer treatments, with organizations like the AACR driving continuous innovation. Further research into the complex genetics of cancer is enabling personalized therapies and early detection strategies, bringing us closer to a future where cancer could become a manageable disease.